A daily newsletter summarizing recent activity & interesting startups globally
RECENT NOTABLE ACTIVITY – MEDICAL DEVICES
- NxStage Medical, a developer of home and critical care dialysis systems, is to be acquired by Fresenius for $2B. Link
- TearScience, an ophthalmalogical medical device maker, is to be acquired by Johnson & Johnson‘s Vision business. Link
- RTI Surgical sold its cardiothoracic closure business to A&E Advanced Closure systems for $60M. Link
- KB Medical, a developer of robotic arm for assistance in spinal procedures, is to be acquired by Globus Medical. Link
- CAS Medical System sold its non-invasive blood pressure monitoring tech portfolio to SunTech Medical for $4.5M. Link
- Entellus Medical, a developer of products for treating chronic sinusitis, raised $50M in a Post IPO round. Link
- Silk Road Medical, a developer of neuroprotaction devices for the Transcarotid artery revascularization procedure, raised $47M in a Series F round, led by Norwest Venture Partners and funds managed by Janus Capital Management. Link
- Amphora Medical, a developer of devices for the treatment of overactive bladder, raised $35.5M in a Series B round led by Longitude Capital and Boston Scientific Corporation. Link
- Allurion Technologies, a developer of procedureless gastric balloon for weight loss, raised $27M in a Series C round led by Romulus Capital. Link
- Simplify Medical, a developer of cervical artificial disc, raised $21M in a Series B round led by Life Sciences Partners. Link
- Neuros Medical, a developer of neurostimulation therapy for chronic neuropathic pain, raised $20M in a Series A round led by U.S. Venture Partners. Link
- Medtronic received FDA and CE Mark approval for its Avalus pericardial aortic surgical valve designed to treat aortic valve disease. Link
- Aum Cardiovascular received FDA 510(k) clearance for its Cadence heart device designed to detect heart murmurs. Link
- Spectranetics received FDA PMA approval for its Stellarex drug-coated balloon designed to treat patients with peripheral arterial disease. Link
SOME INTERESTING STARTUPS FOUND
LEADER BOARD – MEDICAL DEVICES
TriVascular (1998, Santa Rosa, IPO) – Medical devices for endovascular aortic repair. Backed by NEA, Pinnacle Ventures, Greenspring Associates, Kaiser Permanente Ventures, ABS Ventures, MPM Capital, Delphi Ventures, Kearny Venture Partners, De Novo Ventures, Deerfield Capital Management, Helix Ventures, Deerfield, Permal, Pinnacle Ventures, and Rock Springs Capital. Went public in 2014.
Cardiovascular Systems (1989, Saint Paul, IPO) – Devices treating peripheral and coronary vascular disease. Backed by Silicon Valley Bank, Mitsui Global Investment, TPG, Healthcare Ventures, Lumira Capital, and Partners for Growth. Went public in 2006.
ConforMIS (2004, Bedford, IPO) – Personalized, partial knee resurfacing implants to treat knee osteoarthritis. Backed by Aeris Capital, and Centurion. Went public in 2015.
Amedica (1996, Salt Lake City, IPO) – Spinal implants based on silicon nitride ceramic technology platform. Backed by Morningside Ventures, Zions Bank, Oxford Finance, venBio Partners, Hillhouse Capital, Epidarex Capital, and AJU IB Investment U.S. Went public in 2014.
Glaukos (2001, Laguna Hills, IPO) – Developed Micro-Invasive Glaucoma Surgery implant to treat glaucoma. Backed by Orbimed, Meritech Capital, InterWest Partners, Frazier Healthcare Partners, Versant Ventures, Novo A/S, Domain Associates, Fjord Ventures, and Montreux Equity Partners. Went public in 2015.
Ocular Therapeutix (2006, Bedford, IPO) – Develops Ophthalmic therapeutic products by using hydrogel technology. Backed by Polaris Partners, Ascension Ventures, Versant Ventures, SV Life Sciences, Baxter, Pinnacle Ventures, and Ascension Ventures. Went public in 2014.
Senseonics (1996, Germantown, IPO) – Implantable system for continuous glucose monitoring. Backed by NEA, Rho Capital Partners, Greenspring Associates, Rho Ventures, Anthem Capital Management, Abingworth, Delphi Ventures, Healthcare Ventures, and Anthem Capital. Went public in 2016.
Tandem Diabetes (2008, San Diego, IPO) – Device for continuous glucose monitoring and manual insulin delivery. Backed by TPG, HLM Venture Partners, Domain Associates, Delphi Ventures, and Kearny Venture Partners. Went public in 2013.
ViewRay (2004, Oakwood, IPO) – MRI-guided radiation therapy technology for cancer. Backed by Fidelity Investments, Orbimed, Siemens, ITOCHU Technology Ventures, Fidelity Growth Partners Europe, HTGC, Fidelity Biosciences, Kearny Venture Partners, Aisling Capital, Montrose Capital Partners, Xeraya Capital, CRG, and F-Prime Capital Partners. Went public in 2015.
GeneNews (1998, Markham, IPO) – Blood-based molecular diagnostics. Went public in 2001.
Nexstim (2000, Helsinki, IPO) – Noninvasive brain stimulation for rehabilitating stroke patients. Backed by Capricorn Venture Partners, Suomen Teollisuussijoitus, Life Sciences Partners, Lundbeckfond Ventures, Healthcap, Finnish Industry Investment, Lundbeckfonden, and Healthcap. Went public in 2014.
Vycor Medical (2005, Boca Raton, IPO) – Minimally-invasive surgical devices & therapies for neurological disease. Went public in 2009.
Bovie Medical (1970, Clearwater, IPO) – Manufactures electrosurgical products for gynecologic applications. Backed by Great Point Partners. Went public in 2000.
Viveve Medical (2005, Sunnyvale, IPO) – RF therapy for vaginal laxity. Bridge Bank, 5AM Ventures, GBS Venture Partners, Wexford Capital, Square 1 Bank, RTW Investments, and Stone Pine Capital LLC. Went public in 2016.
Inogen (2001, Goleta, IPO) – Portable Oxygen Concentrator for Oxygen Therapy. Backed by Western Technology Investment, Avalon Ventures, Versant Ventures, Novo A/S, Arboretum Ventures, and Accuitive Medical Ventures. Went public in 2014.
Aerogen (2000, Galway, IPO) – Develops Aerosol drug delivery devices. Backed by J.P. Morgan, US Venture Partners, InterWest Partners, Western Technology Investment, Invesco, Wheatley Partners, Viridian Investment Partners, Western Development Commission, and Healthcap. Went public in 2000.
EndoChoice (2008, Alpharetta, IPO) – Device for gastrointestinal conditions. Backed by Sequoia Capital, Silicon Valley Bank, Accelmed, Council Capital, MidCap Financial, Deerfield, River Cities Capital Funds, Agate Medical investments, Rock Springs Capital, and Envest Private Equity. Went public in 2015.
Mauna Kea Tech (2000, Paris, IPO) – Endomicroscopy devices for Gastrointestinal and Respiratory tracts. Backed by Seventure Partners, Psilos, and Finadvance. Went public in 2011.
Dental & Maxillofacial
Align Technology (1997, San Jose, IPO) – Develops Invisalign clear aligners and other dental products. Backed by KPCB, Questmark Partners, ABS Ventures, Oak Hill Capital Partners, The Carlyle Group, and Tekla Capital Management. Went public in 2001.
Biolase (1987, Irvine, IPO) – Develops Dental lasers and scanning devices. Backed by Oracle Investment Management. Went public in 2003.
Entellus Medical (2006, Plymouth, IPO) – Suite of products for treating chronic sinusitis. Backed by Greenspring Associates, Split Rock Partners, Essex Woodlands, SV Life Sciences, Covidien and Oxford Finance. Went public in 2015.
Intersect ENT (2003, Menlo Park, IPO) – Develops drug-releasing implant for sinusitis. Backed by Norwest Venture Partners, KPCB, and US Venture Partners. Went public in 2014.
Leaderboard includes all the top funded, IPO and successfully running bootstrapped companies along with their location, founding year and funding amount.
For latest updates, visit the Medical Devices feed.